CVS Health (CVS)

• Market cap: $66.9B
• 1 day: -3.45%
• 5 days: -4.30%
• 1 month: -18.17%
• 3 months: -7.59%
• 6 months: -5.46%
• Year to date: -34.21%
• 1 year: -23.06%
• 5 years: -28.40%
• 10 years: -40.98%
• Sector: Consumer Discretionary
• Industry: Drug Stores & Proprietary Stores

About: CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.

Employees: 300,000

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

22% more call options, than puts

Call options by funds: $1.77B | Put options by funds: $1.45B

2% more capital invested

Capital invested by funds: $61.9B [Q2] → $62.9B (+$958M) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 27 [Q2] → 27 (+0) [Q3]

3.6% less ownership

Funds ownership: 83.43% [Q2] → 79.82% (-3.6%) [Q3]

5% less funds holding

Funds holding: 1,867 [Q2] → 1,765 (-102) [Q3]

40% less first-time investments, than exits

New positions opened: 153 | Existing positions closed: 255

52% less repeat investments, than reductions

Existing positions increased: 469 | Existing positions reduced: 969

Research analyst outlook

15 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $58 9% upside
• Avg. target: $68 29% upside
• High target: $85 60% upside

15 analyst ratings

• positive: 9 60%
• neutral: 6 40%
• negative: 0 0%

RBC Capital Ben Hendrix 48% 1-year accuracy 32 / 67 met price target	9% upside $58	Outperform Maintained	15 Nov 2024
UBS Kevin Caliendo 81% 1-year accuracy 13 / 16 met price target	17% upside $62	Neutral Maintained	7 Nov 2024
Barclays Andrew Mok 50% 1-year accuracy 29 / 58 met price target	33% upside $71	Overweight Maintained	7 Nov 2024
Wells Fargo Stephen Baxter 36% 1-year accuracy 13 / 36 met price target	13% upside $60	Equal-Weight Maintained	4 Nov 2024
Mizuho Ann Hynes 50% 1-year accuracy 11 / 22 met price target	24% upside $66	Outperform Maintained	24 Oct 2024